Brian Hoffmann - Hikma Pharmaceuticals Pres Generics

All Insiders . USA . 
Stock . Hikma Pharmaceuticals PLC . Stakeholders . Insider . Brian Hoffmann
HKMPF Stock  USD 28.92  0.78  2.77%   

Insider

Brian Hoffmann is Pres Generics of Hikma Pharmaceuticals PLC
Phone44 20 7399 2760
Webhttps://www.hikma.com

Hikma Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Hikma Pharmaceuticals PLC has accumulated 651 M in total debt with debt to equity ratio (D/E) of 0.71, which is about average as compared to similar companies. Hikma Pharmaceuticals PLC has a current ratio of 2.08, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hikma Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Hikma Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hikma Pharmaceuticals PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hikma to invest in growth at high rates of return. When we think about Hikma Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Cheryl TrbulaAsure Software
N/A
Richard RobertsCVR Partners LP
N/A
Bhaskar RamachandranPPG Industries
N/A
Eitan ZamirStratasys
48
Frank AlbertoPark Electrochemical
N/A
Randal RudniskiAsure Software
N/A
Omer KriegerStratasys
N/A
Patricia KroppNL Industries
61
Yossi AzarzarStratasys
62
Jeffrey ConawayCVR Partners LP
49
Patricia AgnelloCVR Partners LP
64
Yoav ZeifStratasys
59
David WillettsCVR Partners LP
N/A
Amy RufNL Industries
50
Guillermo NovoPPG Industries
58
Todd WaletzkiAsure Software
N/A
Michael NallyPPG Industries
45
Kapiljeet DarganCVR Partners LP
38
John PenceAsure Software
53
Yonah LloydStratasys
59
Darci ScottNL Industries
46
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people. Hikma Pharmaceuticals PLC [HKMPF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity0.15
Return On Asset0.077

Hikma Pharmaceuticals PLC Leadership Team

Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Riad Mishlawi, EU Vice President and Global Head - Injectables
Engineer Darwazah, Ex CEO
Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets
Khalid Nabilsi, Chief Officer
CPA CFA, Exec MA
Brian Hoffmann, Pres Generics
Hussein Arkhagha, General Counsel
Samuel Park, Global US
Susan Ringdal, Vice President - Corporate Strategy and Investor Relations
Majda Labadi, Corporate Vice President - Human Resources

Hikma Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.15
Return On Asset0.077
Profit Margin0.14 %
Operating Margin0.22 %
Current Valuation5.26 B
Shares Outstanding220.26 M
Shares Owned By Insiders29.67 %
Shares Owned By Institutions41.69 %
Price To Earning7.89 X
Price To Book1.84 X

Currently Active Assets on Macroaxis

CRMSalesforce
CCitigroup
GMGeneral Motors
WDWalker Dunlop
MSFTMicrosoft

Other Information on Investing in Hikma Pink Sheet

Hikma Pharmaceuticals financial ratios help investors to determine whether Hikma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hikma with respect to the benefits of owning Hikma Pharmaceuticals security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY